Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > What's up with the selling

<< Previous

Bullboard Posts

Next >>

Comment by 2019champson May 12, 2021 2:27pm

93 Views

Post# 33184100

RE:RE:RE:What's up with the selling

Some of these guys are really going to be kicking themselves when we're trading at $10 in the near future. $50 a share isnt out of the question for a drug like this. This drug targets an unmet area. Let these sloppy sellers and sloppy algos regret it

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario